Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer
Summary: The clinical utility of circulating tumor DNA (ctDNA) in hormone-sensitive prostate cancer (HSPC) remains inadequately elucidated. This study presents the largest real-world cohort to conduct a concordance analysis between ctDNA and tissue-based genomic profiling in HSPC patients. The findi...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004224001524 |
| _version_ | 1797326238906318848 |
|---|---|
| author | Bin Yang Tingting Zhao Baijun Dong Wei Chen Guanjie Yang Jun Xie Changcheng Guo Ruiliang Wang Hong Wang Longfei Huang Bo Peng Wei Xue Xudong Yao |
| author_facet | Bin Yang Tingting Zhao Baijun Dong Wei Chen Guanjie Yang Jun Xie Changcheng Guo Ruiliang Wang Hong Wang Longfei Huang Bo Peng Wei Xue Xudong Yao |
| author_sort | Bin Yang |
| collection | DOAJ |
| description | Summary: The clinical utility of circulating tumor DNA (ctDNA) in hormone-sensitive prostate cancer (HSPC) remains inadequately elucidated. This study presents the largest real-world cohort to conduct a concordance analysis between ctDNA and tissue-based genomic profiling in HSPC patients. The findings reveal diminished ctDNA abundance in cases with low tumor burden and demonstrate an increased concordance rate between ctDNA and tissue along with the progression of disease burden. Notably, a substantial number of exclusive genomic alterations (GAs) were identified either in ctDNA or tissue in high-volume metastatic disease. Integrating tissue and ctDNA analysis identified specific gene alterations (BRCA1, BRCA2, CDK12, TP53, PTEN, or RB1) associated with a shorter time to the progression to castration-resistant prostate cancer (CRPC), with an escalated CRPC risk correlated with cumulative GAs. This multicenter, real-world investigation underscores the complementary role of ctDNA and tissue in detecting clinically pertinent GAs, highlighting their potential integration into clinical practice for advanced prostate cancer management. |
| first_indexed | 2024-03-08T06:20:32Z |
| format | Article |
| id | doaj.art-8892d2ec2b204a0f90c9fa6cfc69bf8c |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-03-08T06:20:32Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-8892d2ec2b204a0f90c9fa6cfc69bf8c2024-02-04T04:46:07ZengElsevieriScience2589-00422024-02-01272108931Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancerBin Yang0Tingting Zhao1Baijun Dong2Wei Chen3Guanjie Yang4Jun Xie5Changcheng Guo6Ruiliang Wang7Hong Wang8Longfei Huang9Bo Peng10Wei Xue11Xudong Yao12Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China; Corresponding authorDepartment of Urology, the Shanghai Tenth People’s Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai, China; Research Institute, GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai, ChinaDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Clinical College, Anhui Medical University, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaResearch Institute, GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Corresponding authorDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China; Corresponding authorSummary: The clinical utility of circulating tumor DNA (ctDNA) in hormone-sensitive prostate cancer (HSPC) remains inadequately elucidated. This study presents the largest real-world cohort to conduct a concordance analysis between ctDNA and tissue-based genomic profiling in HSPC patients. The findings reveal diminished ctDNA abundance in cases with low tumor burden and demonstrate an increased concordance rate between ctDNA and tissue along with the progression of disease burden. Notably, a substantial number of exclusive genomic alterations (GAs) were identified either in ctDNA or tissue in high-volume metastatic disease. Integrating tissue and ctDNA analysis identified specific gene alterations (BRCA1, BRCA2, CDK12, TP53, PTEN, or RB1) associated with a shorter time to the progression to castration-resistant prostate cancer (CRPC), with an escalated CRPC risk correlated with cumulative GAs. This multicenter, real-world investigation underscores the complementary role of ctDNA and tissue in detecting clinically pertinent GAs, highlighting their potential integration into clinical practice for advanced prostate cancer management.http://www.sciencedirect.com/science/article/pii/S2589004224001524PhysicsQuantum physics |
| spellingShingle | Bin Yang Tingting Zhao Baijun Dong Wei Chen Guanjie Yang Jun Xie Changcheng Guo Ruiliang Wang Hong Wang Longfei Huang Bo Peng Wei Xue Xudong Yao Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer iScience Physics Quantum physics |
| title | Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer |
| title_full | Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer |
| title_fullStr | Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer |
| title_full_unstemmed | Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer |
| title_short | Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer |
| title_sort | circulating tumor dna and tissue complementarily detect genomic alterations in metastatic hormone sensitive prostate cancer |
| topic | Physics Quantum physics |
| url | http://www.sciencedirect.com/science/article/pii/S2589004224001524 |
| work_keys_str_mv | AT binyang circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT tingtingzhao circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT baijundong circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT weichen circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT guanjieyang circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT junxie circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT changchengguo circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT ruiliangwang circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT hongwang circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT longfeihuang circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT bopeng circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT weixue circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer AT xudongyao circulatingtumordnaandtissuecomplementarilydetectgenomicalterationsinmetastatichormonesensitiveprostatecancer |